Trial
NCT03430687
Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Francisco
Collaborators
Amgen
Condition
Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7
Intervention
Laboratory Biomarker Analysis
Why stopped
Investigators prefer to pursue other studies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-28